Mitochondrial disease: an important cause of end-stage renal failure

Shamima Rahman, Andrew M Hall

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Kidneys are highly aerobic organs. They receive roughly a quarter of the cardiac output and contain a high density of mitochondria, particularly in the cortical tubules, which are required to produce adenosine triphosphate (ATP) in sufficient quantity to power the re-uptake of over 98 % of the filtered load. Given the dependence of renal function on aerobic metabolism, it is not surprising that impairment of normal mitochondrial function-due to insults such as ischaemia, drug toxicity and genetic mitochondrial disease-can lead to kidney failure. In this edition of Pediatric Nephrology, D'Aco and colleagues (doi: 10.1007/s00467-012-2354-y ) describe a patient who developed end-stage renal failure caused by a pathogenic mutation (m.586G > A) in the gene encoding the mitochondrial tRNA for phenylalanine, which adversely affects the translation of mitochondrial DNA. The pathogenicity of this mutation was confirmed in cybrid studies using fibroblasts obtained from the patient. In light of this report, m.586G > A should now be added to the rapidly expanding list of mitochondrial and nuclear gene mutations causing mitochondrial disease with renal involvement. Furthermore, mitochondrial disease should be considered as an underlying aetiology in cases of unexplained renal failure, particularly in the context of a multisystem disorder. Renal replacement therapy is an option for patients with mitochondrial disease, but life expectancy even with this therapy may be limited by co-morbidities.
Original languageEnglish
Pages (from-to)357-361
Number of pages5
JournalPediatric Nephrology
Volume28
Issue number3
Early online date12 Dec 2012
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Mitochondrial Diseases
Chronic Kidney Failure
Mitochondrial Genes
Kidney
Mutation
Renal Insufficiency
Inborn Genetic Diseases
Renal Replacement Therapy
Nephrology
Transfer RNA
Life Expectancy
Drug-Related Side Effects and Adverse Reactions
Phenylalanine
Mitochondrial DNA
Cardiac Output
Virulence
Mitochondria
Ischemia
Fibroblasts
Adenosine Triphosphate

Keywords

  • female
  • humans
  • kidney
  • kidney failure, chronic
  • mitochondrial diseases
  • mutation
  • RNA
  • RNA, transfer, phe

Cite this

Mitochondrial disease : an important cause of end-stage renal failure. / Rahman, Shamima; Hall, Andrew M.

In: Pediatric Nephrology, Vol. 28, No. 3, 03.2013, p. 357-361.

Research output: Contribution to journalArticle

Rahman, Shamima ; Hall, Andrew M. / Mitochondrial disease : an important cause of end-stage renal failure. In: Pediatric Nephrology. 2013 ; Vol. 28, No. 3. pp. 357-361.
@article{05a39153e29a44d786d126a720f2b172,
title = "Mitochondrial disease: an important cause of end-stage renal failure",
abstract = "Kidneys are highly aerobic organs. They receive roughly a quarter of the cardiac output and contain a high density of mitochondria, particularly in the cortical tubules, which are required to produce adenosine triphosphate (ATP) in sufficient quantity to power the re-uptake of over 98 {\%} of the filtered load. Given the dependence of renal function on aerobic metabolism, it is not surprising that impairment of normal mitochondrial function-due to insults such as ischaemia, drug toxicity and genetic mitochondrial disease-can lead to kidney failure. In this edition of Pediatric Nephrology, D'Aco and colleagues (doi: 10.1007/s00467-012-2354-y ) describe a patient who developed end-stage renal failure caused by a pathogenic mutation (m.586G > A) in the gene encoding the mitochondrial tRNA for phenylalanine, which adversely affects the translation of mitochondrial DNA. The pathogenicity of this mutation was confirmed in cybrid studies using fibroblasts obtained from the patient. In light of this report, m.586G > A should now be added to the rapidly expanding list of mitochondrial and nuclear gene mutations causing mitochondrial disease with renal involvement. Furthermore, mitochondrial disease should be considered as an underlying aetiology in cases of unexplained renal failure, particularly in the context of a multisystem disorder. Renal replacement therapy is an option for patients with mitochondrial disease, but life expectancy even with this therapy may be limited by co-morbidities.",
keywords = "female, humans, kidney, kidney failure, chronic, mitochondrial diseases, mutation, RNA, RNA, transfer, phe",
author = "Shamima Rahman and Hall, {Andrew M}",
year = "2013",
month = "3",
doi = "10.1007/s00467-012-2362-y",
language = "English",
volume = "28",
pages = "357--361",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Mitochondrial disease

T2 - an important cause of end-stage renal failure

AU - Rahman, Shamima

AU - Hall, Andrew M

PY - 2013/3

Y1 - 2013/3

N2 - Kidneys are highly aerobic organs. They receive roughly a quarter of the cardiac output and contain a high density of mitochondria, particularly in the cortical tubules, which are required to produce adenosine triphosphate (ATP) in sufficient quantity to power the re-uptake of over 98 % of the filtered load. Given the dependence of renal function on aerobic metabolism, it is not surprising that impairment of normal mitochondrial function-due to insults such as ischaemia, drug toxicity and genetic mitochondrial disease-can lead to kidney failure. In this edition of Pediatric Nephrology, D'Aco and colleagues (doi: 10.1007/s00467-012-2354-y ) describe a patient who developed end-stage renal failure caused by a pathogenic mutation (m.586G > A) in the gene encoding the mitochondrial tRNA for phenylalanine, which adversely affects the translation of mitochondrial DNA. The pathogenicity of this mutation was confirmed in cybrid studies using fibroblasts obtained from the patient. In light of this report, m.586G > A should now be added to the rapidly expanding list of mitochondrial and nuclear gene mutations causing mitochondrial disease with renal involvement. Furthermore, mitochondrial disease should be considered as an underlying aetiology in cases of unexplained renal failure, particularly in the context of a multisystem disorder. Renal replacement therapy is an option for patients with mitochondrial disease, but life expectancy even with this therapy may be limited by co-morbidities.

AB - Kidneys are highly aerobic organs. They receive roughly a quarter of the cardiac output and contain a high density of mitochondria, particularly in the cortical tubules, which are required to produce adenosine triphosphate (ATP) in sufficient quantity to power the re-uptake of over 98 % of the filtered load. Given the dependence of renal function on aerobic metabolism, it is not surprising that impairment of normal mitochondrial function-due to insults such as ischaemia, drug toxicity and genetic mitochondrial disease-can lead to kidney failure. In this edition of Pediatric Nephrology, D'Aco and colleagues (doi: 10.1007/s00467-012-2354-y ) describe a patient who developed end-stage renal failure caused by a pathogenic mutation (m.586G > A) in the gene encoding the mitochondrial tRNA for phenylalanine, which adversely affects the translation of mitochondrial DNA. The pathogenicity of this mutation was confirmed in cybrid studies using fibroblasts obtained from the patient. In light of this report, m.586G > A should now be added to the rapidly expanding list of mitochondrial and nuclear gene mutations causing mitochondrial disease with renal involvement. Furthermore, mitochondrial disease should be considered as an underlying aetiology in cases of unexplained renal failure, particularly in the context of a multisystem disorder. Renal replacement therapy is an option for patients with mitochondrial disease, but life expectancy even with this therapy may be limited by co-morbidities.

KW - female

KW - humans

KW - kidney

KW - kidney failure, chronic

KW - mitochondrial diseases

KW - mutation

KW - RNA

KW - RNA, transfer, phe

U2 - 10.1007/s00467-012-2362-y

DO - 10.1007/s00467-012-2362-y

M3 - Article

C2 - 23233040

VL - 28

SP - 357

EP - 361

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 3

ER -